Oral Idarubicin in Patients with Late Chronic Phase Chronic Myelogenous Leukemia or Chronic Myelomonocytic Leukemia

References

• Faderl S, Talpaz M, Estrov Z, et al. ): The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. ): Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998; 12: 31–80
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, et al. ): Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Willer A, Heimpel H, et al. ): Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group. Leukemia 1997; 11(Suppl 3)506–511
   PubMedGoogle Scholar
• Shepherd PC, Richards SM, Allan NC. Progress with interferon in CML–results of the MRC UK CML III study. Bone Marrow Transplant 1996; 17(Suppl 3)S15–18
   PubMedGoogle Scholar
• Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha nl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54: 1–7
   PubMed Web of Science ®Google Scholar
• Johnson SA, Richardson DS. Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Rev 1998; 12: 52–71
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Vellekoop L, McCredie KB, et al. ): Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 1985; 3: 192–200
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Kontoyiannis D, et al. ): Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte- macrophage colony-stimulating factor. J Clin Oncol 1992; 10: 398–405
   PubMed Web of Science ®Google Scholar
• Lambertenghi-Deliliers G, Annaloro C, Cortellaro M, et al. ): Idarubicin in blastic crisis of chronic myelogenous leukemia. Haematologica 1991; 76: 406–408
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Keating MJ, et al. ): Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 1991; 68: 1201–1207
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ. ): Idarubicin: an anthracycline antineoplastic agent. Clin Pharm 1992; 11: 152–167
   PubMedGoogle Scholar
• Chiodini B, Bassan R, Barbui T. ): Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Leuk Lymphoma 1999; 33: 485–497
   PubMed Web of Science ®Google Scholar
• Ferrazzi E, Woynarowski JM, Arakali A, Brenner DE, Beerman TA. ): DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin. Cancer Commun 1991; 3: 173–180
   PubMedGoogle Scholar
• Stewart DJ, Grewaal D, Green RM, et al. ): Bioavailability and pharmacology of oral idarubicin. Cancer Chemother Pharmacol 1991; 27: 308–314
   PubMed Web of Science ®Google Scholar
• Buckley MM, Lamb HM. ): Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Drugs Aging 1997; 11: 61–86
   PubMed Web of Science ®Google Scholar
• Malik ST, Tucker J, Rohatiner AZ, Brace W, Lister TA. ): Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia. Hematol Oncol 1989; 7: 423–427
   PubMed Web of Science ®Google Scholar
• Lowenthal RM, Lambertenghi-Deliliers G. ): Oral idarubicin as treatment for advanced myelodysplastic syndrome. Haematologica 1991; 76: 398–401
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Haferlach T, Gorschluter M, et al. ): Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 1997; 11(Suppl 5)S22–26
   PubMedGoogle Scholar
• Chachoua A, Green M, Laubenstein L, Wemz J, Muggia FM. ): Phase II study of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma. Cancer Treat Rep 1987; 71: 775–776
   PubMedGoogle Scholar
• Falkson G, Coccia-Portugal MA, Vorobiof DA, Terblanche AP, Dreyer R. ): Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia. Am J Clin Oncol 1986; 9: 311–314
   PubMed Web of Science ®Google Scholar
• Berrebi A, Polliack A. ): Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts. Hamatol Bluttransfus 1990; 33: 342–345
   Google Scholar
• Jackson GH, Taylor PR, Iqbal A, et al. ): The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia 1997; 11: 1193–1196
   PubMed Web of Science ®Google Scholar
• Schleyer E, Kuhn S, Ruhrs H, et al. ): Oral idarubicin pharmacokinetics–correlation of trough level with idarubicin area under curve. Leukemia 1997; 11(Suppl 5)S15–21
   PubMedGoogle Scholar
• Musso M, Porretto F, Crescimanno A, et al. ): Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia. Haematologica 1997; 82: 4–8
   PubMedGoogle Scholar
• Kusnierz-Glaz CR, Normann D, Weinberg R, et al. ): Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematol Oncol 1993; 11: 73–80
   PubMed Web of Science ®Google Scholar
• Carella AM, Carlier P, Pungolino E, et al. ): Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 1993; 7: 196–199
   PubMed Web of Science ®Google Scholar
• Keldsen N, Karle H, Hansen NE, Nissen NI. ): Oral idarubicin in elderly patients with acute myeloid leukemia. Eur J Haematol 1990; 45: 60
   PubMed Web of Science ®Google Scholar
• Robert J, Rigal-Huguet F, Huet S, Pris J, Hurteloup P. ): Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Leukemia 1990; 4: 227–229
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Rigal-Huguet F, Hurteloup P, et al. ): Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent. Eur J Haematol 1989; 42: 182–185
   PubMed Web of Science ®Google Scholar
• Carella AM, Lerma E, Celesti L, et al. ): Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. Br J Haematol 1998; 100: 445–448
   PubMed Web of Science ®Google Scholar
• Ruutu T, Elonen E. ): Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia. Hematol Oncol 1991; 9: 87–92
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Talpaz M. ): Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma 1996; 23: 247–252
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Franklin IM, Kelsey S, et al. ): Mobilisation of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine. Bone Marrow Transplant 1994; 14: S38–41
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Franklin IM, Kelsey SM, et al. ): Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol 1997; 96: 627–634
   PubMed Web of Science ®Google Scholar